Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Arcus Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcus Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arcus Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences (RCUS) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arcus Biosciences and its competitors. According to the industry distribution chart, Arcus Biosciences ranks #999999 out of 702 companies in the Biotechnology industry.
Is Arcus Biosciences' Days Payable too high?
Arcus Biosciences' current Days Payable is 0.00. Based on the distribution chart, Arcus Biosciences ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcus Biosciences has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Days Payable compare to ALMS and DNLI?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #999999 out of 702 companies for Days Payable. This places Arcus Biosciences in the lower half of its industry. The industry median Days Payable is 110.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.69, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arcus Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 110.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcus Biosciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.42, compared to a current price of $29.56 — trading 298.4% above its estimated fair value. The current Days Payable is 0.00. Arcus Biosciences' overall GF Score™ is 44/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcus Biosciences (RCUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued.
The current stock price of $29.56 is trading 298.4% above its estimated GF Value™ of $7.42.
GuruFocus considers Arcus Biosciences to be Significantly Overvalued.
Key valuation signals for RCUS:
Days Payable: 0.00
GF Value™: $7.42 vs. price of $29.56 (298.4% above fair value)
No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
44GF Score
Get the complete analysis for RCUS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCUS has been successfully added to your 
